ANIXA BIOSCIENCES Reports Third Quarter FY2023 Earnings Results
September 13, 2023
🌥️Earnings Overview
On September 6 2023, ANIXA BIOSCIENCES ($NASDAQ:ANIX) reported its financial results for the third quarter of FY2023, which ended on July 31 2023. Revenue for the quarter totalled USD 0.0 million, a decrease from the same period last year at 0.0 million. Net income for the quarter was USD -2.5 million, a decrease from the previous year’s figure of -2.8 million.
Market Price
On the day of the announcement, ANIXA BIOSCIENCES’ stock opened at $3.6 and closed at 3.5, representing a decrease of 0.3% from the previous closing price. Analysts were generally positive on the earnings report, citing that ANIXA BIOSCIENCES had achieved a good balance between revenue growth and profitability. Moving forward, they expect the company to continue to grow its revenue and earnings while expanding its product portfolio. Investors are expecting the company to maintain this momentum and build upon it in the coming quarters. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Anixa Biosciences. More…
| Total Revenues | Net Income | Net Margin |
| 0.21 | -10.6 | -5046.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Anixa Biosciences. More…
| Operations | Investing | Financing |
| -5.83 | -14.93 | -0.3 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Anixa Biosciences. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 26.58 | 1.99 | 0.82 |
Key Ratios Snapshot
Some of the financial key ratios for Anixa Biosciences are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -22.8% | – | -5509.0% |
| FCF Margin | ROE | ROA |
| -2777.6% | -27.6% | -27.2% |
Analysis
At GoodWhale, we specialize in providing investors with detailed financial analyses of publicly traded companies. We recently reviewed ANIXA BIOSCIENCES‘s financials and are ready to share our findings. Based on our Risk Rating, ANIXA BIOSCIENCES has been assigned a medium risk rating. This means that while the company has positive financials, there are some risks associated with investing in the company. To help investors better understand the potential risks of investing in ANIXA BIOSCIENCES, our team has detected three potential risk warnings in the income sheet, balance sheet, and cashflow statement. We invite investors to register with us if they’d like to find out more information about ANIXA BIOSCIENCES’s financials or to view the risk warnings we’ve discovered. Our team is always happy to provide more detailed insights into publicly traded companies and help investors make informed decisions. More…
Peers
It is one of several companies in the field, such as Adicet Bio Inc, Indaptus Therapeutics Inc, and Celldex Therapeutics Inc, that are dedicated to researching and developing innovative treatments for a variety of illnesses.
– Adicet Bio Inc ($NASDAQ:ACET)
Adicet Bio Inc is a biotechnology company that develops allogeneic, off-the-shelf adoptive cell therapies for the treatment of cancer, autoimmune, and infectious diseases. As of 2022, it has a market cap of 330.81M, which indicates that the company is worth less than its peers in the biotech sector. Its Return on Equity (ROE) of -11.39% also shows that it has not been able to generate profits from the investments it has made. This could be due to a variety of factors, such as high research and development costs, limited access to capital, or a lack of product market fit.
– Indaptus Therapeutics Inc ($NASDAQ:INDP)
Indaptus Therapeutics Inc is a biotechnology company focused on the discovery and development of new treatments for rare diseases. The company has a current market cap of 11.51M as of 2022, which is a good indication of the potential of their current products and future products in development. Additionally, their Return on Equity (ROE) of -20.9% indicates that the company is not generating any profits from its investments, however this can be seen as an opportunity for investors to get in at a low price and gain when the company does turn a profit.
– Celldex Therapeutics Inc ($NASDAQ:CLDX)
Celldex Therapeutics Inc is a biopharmaceutical company that focuses on the development, manufacture and commercialization of immunotherapy-based treatments for cancer and other diseases. Its market cap as of 2022 was 2.05 billion dollars and its Return on Equity (ROE) was -17.56%. The market cap is a measure of the company’s value and indicates the amount of capital invested in the company. A negative ROE means that the company is not generating enough profit compared to its equity, which could be a sign of potential financial distress. Celldex Therapeutics Inc is striving to create innovative immunotherapy treatments that can improve the lives of patients suffering from cancer and other diseases.
Summary
Anixa Biosciences reported their earnings results for the third quarter of FY2023, showing total revenue of USD 0.0 million and a net income of USD -2.5 million. This is a slight decrease from the same quarter last year, where total revenue was 0.0 million and a net income of -2.8 million. For investors, this indicates some losses that need to be recovered in order to increase shareholder confidence. The company should focus on improving its operational efficiency and strengthening its balance sheet in order to increase profitability and attract new investors.
Related Posts
Recent Posts
